recently, roche diagnosis announced that used to predict which patients to hepatitis b treatment response of new HBsAg quantitative detection reagent listed on China formally.HBsAg quantitative test used to detect in patients with chronic hepatitis b antigen of second liver surface concentration (HBsAg), help to optimize the treatment of chronic hepatitis b management.
Beijing university first hospital infection diseases department and liver disease, director of the center WangGuiJiang professor noted that chronic hepatitis b treatment principles mainly includes antivirus, immune adjustment, anti-inflammatory protect liver, anti fibrosis and symptomatic treatment.Among them, the antiviral treatment is the key, and chronic hepatitis b patients need to carry on the long-term antiviral treatment management, HB-sAg quantitative detection can be used to predict the response to treatment with lasting, adjust treatment solutions to improve therapeutic effect.Research shows that the treatment of patients with significant decline in quantitative HBsAg treatment ended, and hepatitis b e antigen (HBeAg) serological the conversion rates can achieve %, realize the patients with chronic hepatitis b lasting immune control.
WangGuiJiang professor said: "combined HBVDNA and quantitative detection, predictable HBsAg patients with chronic hepatitis b treatment to PEG-IFN lasting response. HBsAg levels drop speed and large extent indicates that it treatment had good result. Use a combination of the two methods, can better understand the response to treatment with, thus setting indiidualized treatment for the treatment of chronic hepatitis b, optimization."
(responsibility editor: XieXiao)
No comments:
Post a Comment